龍泉股份(002671.SZ)預中標長江引水工程PCCP管採購(二標包)項目
格隆匯10月24日丨龍泉股份(002671.SZ)公佈,2019年10月24日,興化粵海水務有限公司在興化市公共資源交易網發佈了《興化市長江引水工程PCCP管採購(二標包)貨物招標評標結果公示》,確定公司為中標候選人第一名。
項目名稱:興化市長江引水工程PCCP管採購(二標包);項目內容:合同標段範圍內,輸水工程中所有PCCP(預應力鋼筒混凝土管)管道及管配件的設計、製造、檢測以及運輸交貨、安裝技術服務。計劃工期:730天。
此次投標報價9534.57萬元,約佔公司2018年度經審計營業收入的9.42%,項目的履行預計對公司2019-2021年營業收入和營業利潤產生影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.